About Steen Bjerre

This author has not yet filled in any details.
So far Steen Bjerre has created 110 blog entries.

Regional Patient Advocate for sub-Sahara Africa


Early 2016 HAEi appointed five Regional Patient Advocates, dividing a large portion of the world between them. As per 1 July 2017, they are joined by Patricia Karani who will be focusing on the sub-Sahara part of the African continent. Patricia Karani was born in Nairobi, Kenya where she is currently residing. She holds a [...]

FDA approves first subcutaneous C1 Esterase Inhibitor


The U.S. Food and Drug Administration has approved Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent HAE attacks in adolescent and adult patients. The subcutaneous route of administration allows for easier at-home self-injection by the patient or caregiver, once proper training is received. "The approval of Haegarda provides [...]

Thousands helped raise HAE awareness step by step


On and around hae day :-) 2017 a group of HAE patients, caregivers, doctors and people from HAE organizations walked four stages of the Camino in northern Spain. Many more would have liked to take part in this walk but were not able to do so. Therefore HAEi arranged the HAE Global Walk 2017, allowing [...]

Positive Results From the Second Interim Analysis


BioCryst Pharmaceuticals, Inc. has announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in HAE. APeX-1 is a 3-part dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered once-daily (QD) BCX7353 for 28 days, as a preventative treatment to reduce the frequency of [...]

Attune Announces Positive Data from Pre-Clinical Studies


  Attune Pharmaceuticals announces positive results from preclinical safety studies evaluating ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of HAE. The strong safety, high potency, and high selectivity results suggest a wide therapeutic window with once-daily dosing potential of ATN-249. In the preclinical toxicology and safety pharmacology studies, ATN-249 was generally [...]

Lanadelumab Reduces HAE Monthly Attack Rate by 87 %


Shire plc announces positive topline Phase 3 results for the HELP study, a global, multi-center, randomized, double-blind placebo-controlled parallel group trial that evaluated the efficacy and safety of subcutaneously administered lanadelumab versus placebo over 26 weeks in patients 12 years of age or older with HAE. Lanadelumab is an investigational treatment being evaluated for the [...]

2018 HAE Global Conference will take place in Vienna, Austria


Following the very successful HAE conferences in Copenhagen, Denmark in 2012, Washington D.C., USA in 2014, and Madrid, Spain in 2016, HAEi is delighted to announce that the fourth HAE Global Conference will be held in Vienna, Austria in May 2018. Once again HAEi welcomes HAE patients, caregivers, healthcare professionals, and industry representatives to a [...]

Adverum Reports First Quarter 2017 Financial Results


Adverum Biotechnologies, Inc. has reported the financial results for the first quarter ended March 31, 2017. “Adverum is well positioned in the gene therapy space with a robust pipeline and a platform of industry-leading AAV vector technology, including novel vector development capabilities,” said Amber Salzman, Ph.D., president and CEO of Adverum Biotechnologies. “Our strong cash [...]

BioCryst Reports First Quarter 2017 Financial Results


BioCryst Pharmaceuticals, Inc. has announced the financial results for the first quarter ended March 31, 2017. "We have completed enrollment in Part 1 and 2 of the APeX-1 Phase 2 clinical trial of BCX7353 for prevention of angioedema attacks and will report top-line data in the second quarter of 2017 as planned," said Jon P. [...]

Shire delivers strong Q1 2017 revenue growth


Shire plc has announced the unaudited results for the three months ended March 31, 2017. Flemming Ornskov, Shire CEO, commented: "In the first quarter we delivered strong top-line growth. (...) Our priorities for the rest of 2017 remain unchanged: launching new products while driving commercial excellence, generating operational efficiencies, and advancing our pipeline of novel therapies. [...]